✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key Takeaways — Veozah (Fezolinetant) Cost & Alternatives
- Veozah is fezolinetant, the first NK3 receptor antagonist approved for menopausal hot flashes — a genuinely new mechanism that does not use hormones.
- US list price: approximately $550/month (45 mg once daily). With insurance, out-of-pocket costs vary widely; without insurance it is unaffordable for most.
- HRT (hormone replacement therapy) remains far better studied and dramatically cheaper — estrogen-based HRT reduces hot flash frequency by 75–90% vs ~50–60% for fezolinetant.
- Veozah’s key advantage is being non-hormonal — it is the only approved option for women with hormone-sensitive cancers (breast, endometrial) who cannot take estrogen.
- MedsBase offers: Progynova (estradiol valerate) from $24, Evalon Cream (estriol) from $28, Premarin (conjugated estrogens) from $33, Livial (tibolone) from $56.
What Is Veozah (Fezolinetant)?
Veozah is the brand name (Astellas Pharma) for fezolinetant, approved by the FDA in May 2023 as the first non-hormonal prescription medication specifically targeting the mechanism of menopausal vasomotor symptoms (hot flashes and night sweats). It is taken as a 45 mg oral tablet once daily.
Hot flashes are driven by dysregulation in the hypothalamic thermoregulatory zone — specifically, a population of neurons called KNDy neurons (kisspeptin/neurokinin B/dynorphin neurons) that become hyperactive as estrogen levels fall during menopause. These neurons fire neurokinin B (NKB), which binds to neurokinin-3 (NK3) receptors and triggers the cascade that causes hot flashes.
Fezolinetant blocks NK3 receptors, interrupting this signalling pathway without using estrogen — making it the first mechanistically distinct non-hormonal approach to hot flash management with proven efficacy in clinical trials.
How Effective Is Veozah?
The pivotal SKYLIGHT trials showed fezolinetant 45 mg once daily:
- Reduced hot flash frequency by ~3–4 events per day vs placebo (SKYLIGHT 1 and 2)
- Reduced hot flash severity significantly at 4 and 12 weeks
- Improvements were maintained at 52 weeks (SKYLIGHT 4)
To put this in context: most patients on placebo in these trials had 7–10 hot flashes per day at baseline. A reduction of 3–4 events = approximately 40–55% reduction. Compare this with estrogen HRT, which typically reduces hot flash frequency by 75–90%. Fezolinetant is effective — but HRT is more effective where it can be used.
Veozah Cost — The Affordability Problem
At US list price, Veozah is approximately $550 per month — or $6,600 per year. Astellas offers a savings card (commercially insured patients may pay $0/month in the first year), but coverage varies and uninsured patients face the full list price.
| Treatment | Mechanism | Hot Flash Reduction | Monthly Cost (approx) |
|---|---|---|---|
| Veozah (Fezolinetant) | NK3 receptor antagonist | ~50–55% | $550 (US list) |
| Progynova (Estradiol Valerate) | Systemic estrogen HRT | 75–90% | From $24 |
| Premarin (Conjugated Estrogens) | Systemic estrogen HRT | 75–90% | From $33 |
| Livial (Tibolone) | Synthetic steroid (estrogen + progestogen + androgen activity) | 70–80% | From $56 |
| Evalon Cream (Estriol) | Local/low-systemic estrogen | Moderate (vaginal symptoms; less effect on systemic flashes) | From $28 |
Who Should Actually Consider Veozah?
Fezolinetant is most appropriate for:
- Breast cancer survivors — women with hormone receptor-positive (ER+) breast cancer who cannot take estrogen. This is the primary unmet need fezolinetant addresses — it is non-hormonal and does not interact with breast tissue estrogen receptors.
- Women with contraindications to HRT — history of thromboembolic events (DVT/PE), certain cardiovascular conditions, or strong personal preference against hormones.
- Women who tried HRT and could not tolerate it — or who prefer to exhaust non-hormonal options first.
For women without hormone-sensitive cancer history and no contraindications, HRT remains more effective, better studied, and dramatically cheaper. The conversation about which is right should involve a gynaecologist or menopause specialist.
HRT Options Available at MedsBase
All the following are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet packaging:
- Progynova (Estradiol Valerate) — from $24 — Oral estradiol 1 mg or 2 mg for menopausal symptoms. Most widely prescribed form of HRT globally. Always use with a progestogen in women with an intact uterus to protect the endometrium.
- Premarin (Conjugated Estrogens) — from $33 — The original HRT, used in the landmark WHI studies. Available as oral tablets and cream. Still considered the most potent available estrogen formulation for severe vasomotor symptoms.
- Livial (Tibolone) — from $56 — A synthetic steroid taken once daily with estrogenic, progestogenic, and androgenic tissue activity. Used in postmenopausal women (at least 12 months since last period). Does not require separate progestogen in women with intact uterus. Also improves libido and sexual function more consistently than estrogen-only HRT.
- Evalon Cream (Estriol) — from $28 — Topical estriol for vaginal dryness, dyspareunia, and urinary symptoms. Estriol is the weakest estrogen and has minimal systemic absorption — often preferred for local genitourinary symptoms when systemic HRT is not needed or contraindicated.
Veozah Side Effects
- Abdominal pain — ~11% of patients (most common complaint in trials)
- Diarrhoea — ~9%
- Insomnia — ~7%
- Hot flashes worsening initially — not typically; fezolinetant works within 1–2 weeks
- Liver enzyme elevation — a signal seen in trials; Astellas includes liver monitoring warnings; avoid in moderate-severe liver impairment
- Drug interactions — strong CYP1A2 inhibitors (fluvoxamine, enoxacin) increase fezolinetant exposure; avoid combination
Frequently Asked Questions
Is Veozah covered by insurance?
Coverage varies significantly. Many commercial insurance plans cover Veozah under tier 2 or 3, making out-of-pocket costs $30–$100/month with copay assistance cards for eligible patients. Medicare and Medicaid coverage is more variable. Without insurance or assistance programs, the $550/month list price applies.
Does Veozah work as well as HRT for hot flashes?
No — HRT (estrogen) is more effective. Fezolinetant achieves approximately 50–55% reduction in hot flash frequency; estrogen-based HRT typically achieves 75–90%. Fezolinetant’s advantage is being non-hormonal, making it the only approved option for women who cannot take estrogen (e.g., breast cancer survivors).
Can I take Veozah with breast cancer medication?
Fezolinetant has no known interaction with common breast cancer treatments (tamoxifen, aromatase inhibitors). It does not stimulate estrogen receptors. However, any new medication should be discussed with your oncologist — drug interaction databases should be consulted and fezolinetant’s CYP1A2 pathway checked against your current regimen.
How quickly does Veozah work?
Hot flash improvement typically begins within the first 1–2 weeks of treatment. Full benefit is usually apparent by week 4. Unlike HRT, which can take 4–8 weeks to achieve maximum effect, fezolinetant’s NK3 receptor mechanism produces relatively fast onset.
What is the difference between Veozah and Orilissa (elagolix)?
Elagolix (Orilissa) is a GnRH receptor antagonist used for endometriosis pain — it suppresses estrogen production systemically (causing temporary menopause-like side effects). Fezolinetant targets NK3 receptors downstream of GnRH and specifically addresses the thermoregulatory dysregulation causing hot flashes, without broadly suppressing estrogen production. They are mechanistically unrelated despite both being non-hormonal.
Is there a generic version of Veozah?
No. Fezolinetant is a novel, patented molecule approved in 2023. Generic entry is unlikely before the mid-2030s based on typical patent timelines. This reinforces the cost-efficacy comparison with generic HRT (estradiol, conjugated estrogens) which costs $3–$35/month internationally.
Medical Disclaimer: This article is for informational purposes only. Hormone therapy and non-hormonal menopause medications require individualised medical assessment considering personal and family medical history. Do not start or stop any menopausal treatment without consulting your doctor or gynaecologist.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.